Regulatory Briefs: UDI Guru Crowley Heads To Industry; Reclassification Website; Post-Market Planning Board

Jay Crowley, the principle architect of FDA’s UDI regulation, is leaving the agency. FDA announced the launch of a website tracking the reclassification of device types, the accreditation GS1 as a UDI issuing agency and improvements to its device recalls database. More regulatory news.

Jay Crowley, FDA’s senior advisor for patient safety who headed the agency’s work on the unique device identification system regulation, is leaving FDA at the end of December to join USDM Life Sciences, the firm announced Dec. 19. He will start at USDM on Jan. 6, and will focus exclusively on providing business process, technology and compliance solutions for the regulated life science industry. “There is nobody more qualified to help our medical device clients become UDI compliant than the person who developed the FDA's compliance rules,” said Kevin Brown, managing partner at USDM Life Sciences, in a statement.

Crowley has worked at FDA for 27 years, and spent 10 of those years developing the UDI system and global...

Welcome to Medtech Insight

Create an account to read this article

More from Legislation

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Policy & Regulation

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.